Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

34.64
-0.0700-0.20%
Post-market: 35.170.5300+1.53%19:30 EDT
Volume:39.47M
Turnover:1.37B
Market Cap:25.02B
PE:-73.70
High:35.34
Open:34.83
Low:34.02
Close:34.71
52wk High:37.97
52wk Low:11.94
Shares:722.41M
Float Shares:581.00M
Volume Ratio:6.91
T/O Rate:6.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:5.91
PE(LYR):-64.15

Loading ...

Bernstein bullish on Roivant Sciences, initiates with an Outperform

TIPRANKS
·
Mar 20

Roivant Sciences Ltd : Bernstein Initiates Coverage With Outperform Rating; Target Price $35

THOMSON REUTERS
·
Mar 20

Roivant Sciences President and Immunovant CEO Eric Venker disposes of USD 5.65 million in common shares

Reuters
·
Mar 20

Roivant Sciences director Melissa B. Epperly disposes of USD 1.2 million in common shares

Reuters
·
Mar 19

Roivant Sciences (ROIV) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Mar 09

Moderna litigation outcome ‘favorable,’ but leaves some risk, says BofA

TIPRANKS
·
Mar 04

Moderna to Pay $2.25 Billion Settlement to Resolve LNP Patent Dispute

Deep News
·
Mar 04

Guggenheim Sticks to Their Buy Rating for Roivant Sciences (ROIV)

TIPRANKS
·
Mar 04

Roivant Sciences Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 04

BUZZ-Street View: Wall Street views Moderna's legal settlement as clearing a major overhang

Reuters
·
Mar 04

Roivant Sciences price target raised to $34 from $33 at H.C. Wainwright

TIPRANKS
·
Mar 04

Moderna Agrees to Pay up to $2.25 Billion to Settle COVID Vaccine Patent Dispute

Reuters
·
Mar 04

Roivant Sciences Raises Buyback Program to $1 Billion

Dow Jones
·
Mar 04

BRIEF-Genevant Sciences And Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Reuters
·
Mar 04

Roivant Sciences - Arbutus Is Currently Evaluating a Return of Capital to Shareholders for Q3 of Calendar Year 2026

THOMSON REUTERS
·
Mar 04

Roivant Sciences: Under Settlement, Genevant to Give Moderna Non-Exclusive License to Lnp Delivery Technology for Infectious Disease Applications

THOMSON REUTERS
·
Mar 04

Roivant Sciences : Board Approved $1 Bln Share Repurchase Program, Inclusive of $500 Mln Authorization That Was Approved in June 2025

THOMSON REUTERS
·
Mar 04

Priovant wins FDA Priority Review for brepocitinib dermatomyositis NDA

Reuters
·
Mar 03

Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis

THOMSON REUTERS
·
Mar 03

Roivant Sciences Ltd - FDA Assigns Pdufa Date Q3 2026, Launch Expected September 2026

THOMSON REUTERS
·
Mar 03